Proteasome and DegP Protease, Mechanisms and Drug Design

View Proteasome and DegP Protease, Mechanisms and Drug Design Proteasome and DegP Protease, Mechanisms and Drug Design Lindau-Nobel Robert Huber 2012

Presenter: Robert Huber

Published: July 2014

Age: 18-22 and upwards

Views: 687 views

Tags: protein;ubiquitin;proteasome;protease;drug

Type: Lectures

Source/institution: Lindau-Nobel

VN:F [1.9.22_1171]
Rating: 0.0/5 (0 votes cast)

Watch now

Within cells or subcellular compartments, mis-folded and/or short-lived regulatory proteins are degraded by protease machines, cage-forming multi-subunit assemblages, the proteasome and HtrA/DegP.  They are essential components in very complex regulatory pathways and interaction networks, the UPS (ubiquitin proteasome system) and the UPR (unfolded protein response), respectively.  Their activity is precisely regulated by maturation from inactive precursors and sequestration of their proteolytic active sites within the particles (proteasome) and by activation of latent forms and oligomerization upon signaling by substrate (HtrA/DegP).  Both systems have proven (proteasome) or promise (HtrA/DegP) to be valuable targets for novel therapeutic drugs and antibiotics.  The analyses of numerous crystal structures of the proteasome and the HtrA/DegP protein families complexed with ligands in conjunction with functional studies have provided a sound basis of structure-based design and development of many novel chemical entities as potential clinical candidates.

Comments are closed.